Composition for inhibiting and preventing myopathy, containing bean leaf extract as active ingredient

Abstract

The present invention relates to a composition for inhibiting and preventing myopathy having a bean leaf extract as an active ingredient. The composition has an effect of inhibiting the overexpression of Atrogin1 and Murf1 specifically expressed in myocyte and restoring cell activity of myocyte to inhibit and prevent muscle loss by including the extract of bean leaf at stage R6 to R8 during the growth stage of bean.

1 . A composition for inhibiting and preventing myopathy comprising a bean leaf extract as an active ingredient. 
     
     
         2 . The composition for inhibiting and preventing myopathy according to  claim 1 , wherein the myopathy is at least one selected from the group consisting of sarcopenia, muscle loss and amyotrophic diseases. 
     
     
         3 . The composition for inhibiting and preventing myopathy according to  claim 1 , wherein the myopathy is senile myopathy. 
     
     
         4 . The composition for inhibiting and preventing myopathy according to  claim 1 , wherein the composition increases cell activity of myocyte. 
     
     
         5 . The composition for inhibiting and preventing myopathy according to  claim 1 , wherein the composition inhibits expression or activity of ubiquitin ligase of skeletal muscle. 
     
     
         6 . The composition for inhibiting and preventing myopathy according to  claim 1 , wherein the composition inhibits expression of Atrogin1 or Murf1 gene. 
     
     
         7 . The composition for inhibiting and preventing myopathy according to  claim 1 , wherein the bean leaf extract is an extract of bean leaf corresponding to any one of stage R6 to R8 during the growth stage of bean. 
     
     
         8 . The composition for inhibiting and preventing myopathy according to  claim 7 , wherein the extract of bean leaf is an extract of bean leaf at stage R7 during the growth stage of bean. 
     
     
         9 . The composition for inhibiting and preventing myopathy according to  claim 7 , wherein the bean is at least one selected from the group consisting of  Rhynchosia Nolubilis, Glycine max ( L .)  Merr., Vicia faba, Phaseolus vulgaris, Phaseolus vulgaris  L.,  Vigna angularis, Phaseolus angularis  W.F. WIGHT.,  Pisum sativum L.  and  Glycine max  MERR. 
     
     
         10 . The composition for inhibiting and preventing myopathy according to  claim 1 , wherein the bean leaf extract is extracted by a solvent selected from the group consisting of water, an organic solvent or a mixture thereof. 
     
     
         11 . The composition for inhibiting and preventing myopathy according to  claim 1 , wherein the bean leaf extract is extracted sequentially by ethanol and ethyl acetate. 
     
     
         12 . The composition for inhibiting and preventing myopathy according to  claim 1 , wherein the bean leaf extract is obtained by a method which comprises the steps of:
 extracting bean leaf with water, an organic solvent or a mixture thereof to obtain the first extract;   adding an organic solvent to the first extract to obtain the second extract; and   concentrating under reduced pressure and drying the final extract containing the first and second extracts.   
     
     
         13 . The composition for inhibiting and preventing myopathy according to  claim 1 , wherein the bean leaf extract is at least one selected from the group consisting of extract of raw bean leaf, and fractions, dried products, dried fractions, fermented products and concentrates thereof. 
     
     
         14 . The composition for inhibiting and preventing myopathy according to  claim 1 , wherein the composition is any one of a food composition, a pharmaceutical composition and a cosmetic composition. 
     
     
         15 . The composition for inhibiting and preventing myopathy according to  claim 14 , wherein the pharmaceutical composition is a composition of an oral formulation.